glycopyrronium (Seebri Breezhaler)
Following a full submission:
glycopyrronium inhalation powder (Seebri Breezhaler®) is accepted for use within NHS Scotland.
Indication under review: as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
In two phase III studies, glycopyrronium was statistically superior to placebo in improving lung function (forced expiratory volume in 1 second [FEV1]) after 12 weeks.
|Drug Name:||glycopyrronium (Seebri Breezhaler)|
|SMC Drug ID:||829/12|
|Manufacturer:||Novartis Pharmaceuticals UK Ltd|
|Indication:||For a once daily maintenance bronchodilator treatment to relieve symptoms in patients with COPD.|
|Sub Category:||3.1 Bronchodilators|
|Submission Type:||Full submission|
|Date Advice Published:||14 January 2013|